rs1045487

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_001372051.1(CASP8):​c.960G>A​(p.Lys320Lys) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0725 in 1,613,906 control chromosomes in the GnomAD database, including 7,856 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.10 ( 1334 hom., cov: 32)
Exomes 𝑓: 0.069 ( 6522 hom. )

Consequence

CASP8
NM_001372051.1 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:4

Conservation

PhyloP100: 0.321

Publications

30 publications found
Variant links:
Genes affected
CASP8 (HGNC:1509): (caspase 8) This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes composed of a prodomain, a large protease subunit, and a small protease subunit. Activation of caspases requires proteolytic processing at conserved internal aspartic residues to generate a heterodimeric enzyme consisting of the large and small subunits. This protein is involved in the programmed cell death induced by Fas and various apoptotic stimuli. The N-terminal FADD-like death effector domain of this protein suggests that it may interact with Fas-interacting protein FADD. This protein was detected in the insoluble fraction of the affected brain region from Huntington disease patients but not in those from normal controls, which implicated the role in neurodegenerative diseases. Many alternatively spliced transcript variants encoding different isoforms have been described, although not all variants have had their full-length sequences determined. [provided by RefSeq, Jul 2008]
CASP8 Gene-Disease associations (from GenCC):
  • autoimmune lymphoproliferative syndrome type 2B
    Inheritance: AR Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.61).
BP6
Variant 2-201284973-G-A is Benign according to our data. Variant chr2-201284973-G-A is described in ClinVar as Benign. ClinVar VariationId is 333505.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=0.321 with no splicing effect.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.248 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CASP8NM_001372051.1 linkc.960G>A p.Lys320Lys synonymous_variant Exon 8 of 9 ENST00000673742.1 NP_001358980.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CASP8ENST00000673742.1 linkc.960G>A p.Lys320Lys synonymous_variant Exon 8 of 9 NM_001372051.1 ENSP00000501268.1 Q14790-1

Frequencies

GnomAD3 genomes
AF:
0.104
AC:
15765
AN:
151950
Hom.:
1326
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.209
Gnomad AMI
AF:
0.0658
Gnomad AMR
AF:
0.0493
Gnomad ASJ
AF:
0.0818
Gnomad EAS
AF:
0.201
Gnomad SAS
AF:
0.260
Gnomad FIN
AF:
0.0389
Gnomad MID
AF:
0.165
Gnomad NFE
AF:
0.0452
Gnomad OTH
AF:
0.103
GnomAD2 exomes
AF:
0.0948
AC:
23830
AN:
251464
AF XY:
0.101
show subpopulations
Gnomad AFR exome
AF:
0.218
Gnomad AMR exome
AF:
0.0292
Gnomad ASJ exome
AF:
0.0840
Gnomad EAS exome
AF:
0.196
Gnomad FIN exome
AF:
0.0399
Gnomad NFE exome
AF:
0.0490
Gnomad OTH exome
AF:
0.0698
GnomAD4 exome
AF:
0.0692
AC:
101220
AN:
1461836
Hom.:
6522
Cov.:
35
AF XY:
0.0747
AC XY:
54313
AN XY:
727220
show subpopulations
African (AFR)
AF:
0.220
AC:
7377
AN:
33474
American (AMR)
AF:
0.0327
AC:
1462
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.0846
AC:
2211
AN:
26136
East Asian (EAS)
AF:
0.226
AC:
8958
AN:
39700
South Asian (SAS)
AF:
0.251
AC:
21680
AN:
86254
European-Finnish (FIN)
AF:
0.0409
AC:
2186
AN:
53418
Middle Eastern (MID)
AF:
0.148
AC:
853
AN:
5768
European-Non Finnish (NFE)
AF:
0.0463
AC:
51500
AN:
1111966
Other (OTH)
AF:
0.0827
AC:
4993
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.486
Heterozygous variant carriers
0
5820
11640
17459
23279
29099
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
2260
4520
6780
9040
11300
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.104
AC:
15805
AN:
152070
Hom.:
1334
Cov.:
32
AF XY:
0.107
AC XY:
7946
AN XY:
74336
show subpopulations
African (AFR)
AF:
0.209
AC:
8667
AN:
41400
American (AMR)
AF:
0.0493
AC:
753
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
0.0818
AC:
284
AN:
3472
East Asian (EAS)
AF:
0.201
AC:
1040
AN:
5176
South Asian (SAS)
AF:
0.260
AC:
1253
AN:
4812
European-Finnish (FIN)
AF:
0.0389
AC:
412
AN:
10586
Middle Eastern (MID)
AF:
0.163
AC:
48
AN:
294
European-Non Finnish (NFE)
AF:
0.0452
AC:
3073
AN:
68018
Other (OTH)
AF:
0.102
AC:
215
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.509
Heterozygous variant carriers
0
651
1303
1954
2606
3257
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
176
352
528
704
880
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0615
Hom.:
1333
Bravo
AF:
0.107
Asia WGS
AF:
0.227
AC:
789
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Autoimmune lymphoproliferative syndrome type 2B Benign:2
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.61
CADD
Benign
6.0
DANN
Benign
0.69
PhyloP100
0.32
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Mutation Taster
=97/3
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1045487; hg19: chr2-202149696; COSMIC: COSV51848852; COSMIC: COSV51848852; API